awmsg logo



emtricitabine/tenofovir disoproxil fumarate (Truvada®)


Reference No. 1625

Publication date:
12/09/2017


Appraisal information

emtricitabine/tenofovir disoproxil fumarate (Truvada®) 200 mg/245 mg film-coated tablet


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 08/03/2017
AWMSG meeting date: 26/04/2017
   
   
Submission Type: Full Submission
Status: Not recommended
Advice No: 0817
Ministerial ratification: 11/09/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Emtricitabine/tenofovir disoproxil fumarate (Truvada®) is not recommended for use within NHS Wales in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV 1 infection in adults at high risk. The case for cost-effectiveness has not been proven. Subsequent to AWMSG recommendation, this medicine has been made available in Wales. Truvada for use as pre-exposure prophylaxis is being provided through NHS Wales from 17 July 2017 for up to three years. During this time, all those who are eligible will receive Truvada and data will be collected on adherence, acceptability and HIV/STI status. This information will help assess its effectiveness at preventing HIV and address some of the concerns of AWMSG in relation to cost effectiveness. Data collected will help inform any future decision about the drugs provision though NHS Wales.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download